Jennifer A Wargo Selected Research

PLX 4720

8/2017	Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations.
1/2015	Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.
12/2013	Potential role of 5-aza-2'-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancer.
1/2013	BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jennifer A Wargo Research Topics

Disease

130	Neoplasms (Cancer) 04/2022 - 03/2009
117	Melanoma (Melanoma, Malignant) 08/2022 - 09/2004
15	Neoplasm Metastasis (Metastasis) 01/2022 - 12/2013
6	Disease Progression 01/2021 - 04/2014
6	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 08/2014
5	Testicular Neoplasms (Testicular Cancer) 08/2014 - 05/2008
4	Squamous Cell Carcinoma of Head and Neck 04/2022 - 01/2019
4	Infections 04/2022 - 01/2016
4	Sarcoma (Soft Tissue Sarcoma) 01/2020 - 01/2018
3	Merkel Cell Carcinoma 03/2022 - 11/2016
3	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 03/2016
3	Pathologic Complete Response 10/2021 - 01/2019
3	Tertiary Lymphoid Structures 01/2020 - 01/2020
3	Renal Cell Carcinoma (Grawitz Tumor) 09/2018 - 08/2014
2	Lung Neoplasms (Lung Cancer) 01/2022 - 10/2016
2	Skin Neoplasms (Skin Cancer) 01/2022 - 11/2014
2	Experimental Melanoma 11/2020 - 06/2005
2	Adenocarcinoma 01/2020 - 01/2017
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2020 - 01/2016
2	Colitis 01/2019 - 12/2018
2	Breast Neoplasms (Breast Cancer) 01/2019 - 12/2014
2	Colonic Neoplasms (Colon Cancer) 01/2017 - 07/2015
2	Uveal melanoma 01/2017 - 01/2016
2	Urinary Bladder Neoplasms (Bladder Cancer) 11/2016 - 08/2014
2	Hypoxia (Hypoxemia) 10/2016 - 12/2013
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2013 - 09/2012
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 04/2022
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 03/2022
1	Head and Neck Neoplasms (Head and Neck Cancer) 01/2022
1	Glioma (Gliomas) 01/2022
1	Mouth Neoplasms (Oral Cancer) 01/2022
1	Carcinogenesis 01/2022

Drug/Important Bio-Agent (IBA)

46	Immune Checkpoint InhibitorsIBA 01/2022 - 03/2013
23	Biomarkers (Surrogate Marker)IBA 06/2022 - 07/2013
22	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022 - 12/2010
12	AntigensIBA 01/2022 - 06/2005
12	Pharmaceutical PreparationsIBA 01/2021 - 03/2013
11	VemurafenibIBA 01/2018 - 03/2012
10	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2022 - 03/2009
10	IpilimumabIBA 01/2021 - 08/2014
8	Proteins (Proteins, Gene)FDA Link 01/2022 - 06/2010
8	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2014
8	Phosphotransferases (Kinase)IBA 01/2021 - 07/2010
6	Messenger RNA (mRNA)IBA 01/2022 - 01/2014
6	dabrafenibIBA 01/2021 - 03/2013
6	trametinibIBA 01/2021 - 03/2013
6	Mitogen-Activated Protein KinasesIBA 01/2017 - 07/2010
5	Neoplasm Antigens (Tumor Antigens)IBA 01/2022 - 03/2009
5	NivolumabIBA 01/2021 - 01/2018
5	LigandsIBA 05/2019 - 10/2012
5	CytokinesIBA 11/2016 - 06/2010
4	Biological ProductsIBA 01/2021 - 10/2017
4	Peptides (Polypeptides)IBA 01/2021 - 09/2004
4	pembrolizumabIBA 01/2020 - 10/2016
4	PLX 4720IBA 08/2017 - 01/2013
3	Chimeric Antigen ReceptorsIBA 01/2022 - 11/2016
3	Interleukin-2 (IL2)IBA 01/2022 - 01/2015
3	atezolizumabIBA 12/2021 - 07/2014
3	Transcription Factors (Transcription Factor)IBA 01/2019 - 10/2014
3	Decitabine FDA Link 08/2014 - 03/2009
3	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 12/2013 - 12/2010
2	Therapeutic UsesIBA 04/2022 - 03/2009
2	MicroRNAs (MicroRNA)IBA 01/2022 - 10/2021
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 01/2017
2	16S Ribosomal RNAIBA 01/2022 - 01/2021
2	B7-H1 AntigenIBA 01/2022 - 10/2021
2	AntibodiesIBA 12/2021 - 09/2019
2	HLA-A Antigens (HLA-A)IBA 01/2018 - 05/2008
2	aldesleukin (Proleukin)FDA Link 01/2018 - 01/2015
2	cediranib (AZD2171)IBA 08/2017 - 01/2015
2	Immunomodulating AgentsIBA 02/2017 - 11/2016
2	Microphthalmia-Associated Transcription FactorIBA 04/2016 - 10/2014
2	Mechanistic Target of Rapamycin Complex 1IBA 12/2014 - 07/2013
2	Oncogene Proteins (Oncogene Protein)IBA 12/2014 - 11/2012
2	Interferon-gamma (Interferon, gamma)IBA 08/2014 - 03/2009
2	MitogensIBA 07/2013 - 03/2013
2	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 03/2013 - 07/2010
2	HLA-A*02:01 antigenIBA 01/2011 - 09/2004
1	Non-Narcotic Analgesics (Analgesics, Non Narcotic)IBA 03/2022
1	Opioid Analgesics (Opioids)IBA 03/2022
1	Analgesics (Analgesic Drugs)IBA 03/2022
1	Long Noncoding RNAIBA 01/2022
1	Bacterial DNAIBA 01/2022
1	DNA (Deoxyribonucleic Acid)IBA 01/2022
1	Dietary Fiber FDA Link 12/2021
1	Pantothenic Acid (Calcium Pantothenate)FDA Link 12/2021
1	Coenzyme A (CoA)IBA 12/2021

Therapy/Procedure

99	Therapeutics 06/2022 - 03/2009
61	Immunotherapy 04/2022 - 09/2004
12	Neoadjuvant Therapy 08/2022 - 07/2018
6	Fecal Microbiota Transplantation 10/2021 - 12/2018
6	Drug Therapy (Chemotherapy) 01/2021 - 08/2015
6	Precision Medicine 01/2018 - 09/2015
4	Radiotherapy 01/2021 - 08/2015
3	Lymph Node Excision (Lymph Node Dissection) 03/2022 - 06/2009
2	Induction Chemotherapy 01/2020 - 01/2016
2	Investigational Therapies (Experimental Therapy) 09/2012 - 03/2009
2	Metastasectomy 12/2010 - 06/2009
1	Transplantation 04/2022
1	Chemoradiotherapy 01/2022